Presented by Taconic Biosciences and Cergentis
Random transgenesis has been widely used since the 90s to generate transgenic strains, and it continues to be used today as one of the many tools in the current model generation toolbox. Although this technology has many advantages, the random nature of integration can pose challenges, particularly for related sets of models generated as different founder lines from the same transgene. Transgenes can integrate with various copy numbers and structures, affecting correct expression, and may even disrupt important endogenous genes depending on where they insert.
Transgene mapping analysis via Cergentis’ proprietary Targeted Locus Amplification (TLA) technology is a powerful strategy designed to help researchers overcome these challenges and fully characterize transgene integration in mouse and rat lines. Transgene mapping identifies the precise integration location(s) for a transgene.
This informative webinar will present a real-world case study in the application of transgene mapping analysis via TLA to humanized ACE2 (hACE2) mouse lines used for coronavirus research. Specifically we will highlight how Taconic and Cergentis applied this technology to a set of related hACE2 models generated from injection of the same transgene.
Expect to learn more about:
Dr. Martijn Kelder obtained his MSc in molecular genetics from Utrecht University, after which he further specialized in the mechanisms of genome editing using CRISPR/Cas9 during his doctoral training at the University of Edinburgh. He has co-authored in several journals including PLoS Biology and Nature Protocols. At Cergentis, Martijn is leading sales and business development for the applications of TLA in the support of the genetic engineering of animal models, pharmaceutical cell lines and cell and gene therapy by leading pharma and biotech.
Dr. Terina Martinez is a Field Application Scientist with Taconic Biosciences, and has deep expertise in target validation, animal model generation and characterization, and optimization of preclinical study design. Terina earned her doctorate degree from the University of Texas Southwestern Medical Center and did postdoctoral work at the University of Pittsburgh focusing on mechanisms of neuroinflammation and the role of the immune system in neurodegeneration. Prior to joining Taconic, Terina was with The Michael J. Fox Foundation for Parkinson’s Research, where she served as Senior Associate Director for Research Programs and led the Foundation’s Preclinical Tools and Animal Models, Inflammation, and Emerging Targets programs.
© 2021 Taconic Biosciences, Inc. All rights reserved.